Overview

Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2006-12-05
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known which combination chemotherapy regimen followed by radiation therapy is more effective in treating aggressive non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two combination chemotherapy regimens followed by radiation therapy to compare how well they work in treating patients with aggressive non-Hodgkin's lymphoma.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
German High-Grade Non-Hodgkin's Lymphoma Study Group
Treatments:
Cyclophosphamide
Doxorubicin
Etoposide
Liposomal doxorubicin
Prednisone
Vincristine
Criteria
DISEASE CHARACTERISTICS:

- Histologically confirmed aggressive non-Hodgkin's lymphoma

- Previously untreated disease

- Favorable prognosis

- International Prognostic Index score of 0-1

- No more than 25% marrow involvement

PATIENT CHARACTERISTICS:

Age

- 18 to 60

Performance status

- ECOG 0-3 OR

- Karnofsky 40-100%

Life expectancy

- Not specified

Hematopoietic

- Platelet count at least 100,000/mm^3

- WBC at least 2,500/mm^3

Hepatic

- No active hepatitis infection

Renal

- Not specified

Other

- HIV negative

- Not pregnant or nursing

- No relevant accompanying disease

- No other concurrent malignancy

- No contraindications to any study medications

- No prior noncompliance by patient

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- No prior chemotherapy

Endocrine therapy

- Not specified

Radiotherapy

- No prior radiotherapy

Surgery

- Not specified

Other

- No other concurrent participation in another treatment study